- Home
- GNTA vs OPTN Comparison
GNTA vs OPTN Comparison
Compare GNTA & OPTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNTA
- OPTN
- Stock Information
- Founded
- GNTA 2014
- OPTN 2010
- Country
- GNTA Italy
- OPTN United States
- Employees
- GNTA N/A
- OPTN N/A
- Industry
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- OPTN Biotechnology: Pharmaceutical Preparations
- Sector
- GNTA Health Care
- OPTN Health Care
- Exchange
- GNTA Nasdaq
- OPTN Nasdaq
- Market Cap
- GNTA 96.9M
- OPTN 99.7M
- IPO Year
- GNTA 2021
- OPTN 2017
- Fundamental
- Price
- GNTA $4.80
- OPTN $0.40
- Analyst Decision
- GNTA Strong Buy
- OPTN Strong Buy
- Analyst Count
- GNTA 1
- OPTN 3
- Target Price
- GNTA $25.00
- OPTN $3.00
- AVG Volume (30 Days)
- GNTA 7.4K
- OPTN 1.1M
- Earning Date
- GNTA 01-01-0001
- OPTN 11-12-2024
- Dividend Yield
- GNTA N/A
- OPTN N/A
- EPS Growth
- GNTA N/A
- OPTN N/A
- EPS
- GNTA N/A
- OPTN N/A
- Revenue
- GNTA N/A
- OPTN $75,672,000.00
- Revenue This Year
- GNTA N/A
- OPTN $24.44
- Revenue Next Year
- GNTA N/A
- OPTN $49.00
- P/E Ratio
- GNTA N/A
- OPTN N/A
- Revenue Growth
- GNTA N/A
- OPTN 5.13
- 52 Week Low
- GNTA $2.20
- OPTN $0.32
- 52 Week High
- GNTA $7.28
- OPTN $2.10
- Technical
- Relative Strength Index (RSI)
- GNTA 46.40
- OPTN 28.41
- Support Level
- GNTA $4.44
- OPTN $0.32
- Resistance Level
- GNTA $5.20
- OPTN $0.46
- Average True Range (ATR)
- GNTA 0.44
- OPTN 0.07
- MACD
- GNTA -0.04
- OPTN -0.03
- Stochastic Oscillator
- GNTA 34.29
- OPTN 15.45
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. Its product includes XHANCE (fluticasone propionate) nasal spray, 93 micrograms, a therapeutic utilizing its proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids.